Home > Insider Trading > Filing (0000921895-14-002138)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1561743	Kindred Biosciences Inc.	KIN	Pharmaceutical Preparations (2834)	461160142

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1454385	Oleg Nodelman	C/O Kindred Biosciences, Inc. 1499 Bayshore Highway, Suite 226 Burlingame CA 94010		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-09-29	44,410	$9.56	490,936	No	4	P	Indirect	By EcoR1 Capital Fund, L.P.
Common Stock	Acquisiton	2014-09-29	55,590	$9.56	614,495	No	4	P	Indirect	By EcoR1 Capital Fund Qualified, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By EcoR1 Capital Fund, L.P.
No	4	P	Indirect	By EcoR1 Capital Fund Qualified, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	50,000	Direct

Footnotes

Shares owned directly by EcoR1 Capital Fund, L.P. ("Capital Fund"). Mr. Nodelman, solely by virtue of his position as the manager of EcoR1 Capital, LLC ("EcoR1"), the general partner of Capital Fund, may be deemed to beneficially own the shares owned directly by Capital Fund. Mr. Nodelman expressly disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Shares owned directly by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). Mr. Nodelman, solely by virtue of his position as the manager of EcoR1, the general partner of Qualified Fund, may be deemed to beneficially own the shares owned directly by Qualified Fund. Mr. Nodelman expressly disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The shares owned directly by each of Capital Fund and Qualified Fund have been adjusted from the previous Form 4 filed by Mr. Nodelman with respect to securities of the Issuer to give effect to transfers of shares between Capital Fund and Qualified Fund in connection with periodic rebalancing transactions, which occurred prior to the transactions reported herein.